MOG and myeloid sarcoma: A recent study identified CSF MOG‐IgG positivity in 4/282 (1.4%) controls (MS, intracranial metastases, epilepsy, cord infarct), 66/74 (89%) seropositive MOGAD patients, and 9/73 (12%) seronegative patients with a potential MOGAD phenotype.13